Well, investors, NuVasive (NUVA) just couldn't wait to tell you the good news. Ahead of its presentation at the JPMorgan Healthcare Conference and its official Q4 earnings press release, the company revealed its full year 2012 revenue results. In this video, health care analyst Max Macaluso discusses why this news drove shares up by more than 10% and what investors should watch in 2013.
Free Article
You're reading a free article with opinions that may differ from The Motley Fool's Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
1 Medical Device Preview Investors Were Hoping For
By Max Macaluso
–
Jan 9, 2013 at 2:43PM
NASDAQ: NUVA
NuVasive
Good news today at NuVasive.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson and Medtronic. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Stocks Mentioned
NuVasive
NUVA
Johnson & Johnson
JNJ
$152.45
(0.29%)
$0.44
Stryker
SYK
$393.55
(0.81%)
$3.15
Medtronic
MDT
$86.19
(0.84%)
$0.72
*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.
Related Articles
NuVasive, Inc (NUVA) Q3 2021 Earnings Call Transcript
This Revolutionary Medical Device Company Goes to 11
NuVasive, inc (NUVA) Q2 2021 Earnings Call Transcript
NuVasive Inc (NUVA) Q4 2020 Earnings Call Transcript
NuVasive Inc (NUVA) Q3 2020 Earnings Call Transcript
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.